John Frederick Ek - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: CFO
Signature: /s/ John Frederick Ek
Issuer symbol: AKYA
Transactions as of: 08 Jul 2025
Transactions value $: $0
Form type: 4
Filing time: 10 Jul 2025, 20:39:37 UTC
Previous filing: 03 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ek John Frederick	CFO	C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH	/s/ John Frederick Ek	10 Jul 2025	0001767921

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Other		-54.5K	-21.94%		194K	08 Jul 2025	Direct	F1, F2
transaction	AKYA	Common Stock	Other		-194K	-100%		0	08 Jul 2025	Direct	F1, F2, F3
transaction	AKYA	Common Stock	Other		-20K	-100%		0	08 Jul 2025	Ek Trust Dated November 20, 2020	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Other	$0	-160K	-100%	$0.00	0	08 Jul 2025	Common Stock	160K	$7.60	Direct	F4, F5
transaction	AKYA	Employee Stock Option (Right to Buy)	Other	$0	-70K	-100%	$0.00	0	08 Jul 2025	Common Stock	70K	$5.35	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John Frederick Ek is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2	In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3	Represents aggregate share value of Issuer restricted stock units ("RSU") unvested immediately prior to the Closing Date (each individual RSU, a "Rollover RSU"). On the Closing Date, each Rollover RSU was automatically converted into the right to receive the Per Share Merger Consideration for each share of Issuer common stock subject to such Rollover RSU upon vesting, subject to the same terms and conditions of each Rollover RSU in effect immediately prior to the effectiveness of the Merger.
F4	Disposition of options pursuant to Merger Agreement.
F5	Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.